만성B형간염 치료를 위한 경구용 항바이러스제|RISS 상세보기

다국어 초록 (Multilingual Abstract)

The goal of antiviral therapy for chronic hepatitis B virus (HBV) infection is to eliminate or suppress HBV with the aim of preventing the devastating complications of cirrhosis, hepatic failure, and hepatocellular carcinoma. Oral antiviral agents suppress but do not eradicate HBV, therefore long-term treatment is necessary to achieve the sustained suppression of viral replication. To optimize the treatment response, treatment should be initiated at an appropriate time with the best available drugs. The indications for treatment are generally based on HBeAg status, serum HBV-DNA level, serum alanine aminotransferase, and the severity of the liver disease. Patients with clinical evidence of active viral replication either with liver inflammation or potentially evolving to cirrhosis should be treated. Nowadays, lamivudine, adefovir, clevudine, telbivudine, entecavir, and tenofovir have been approved for chronic hepatitis B (CHB). Among these, tenofovir and entecavir are potent HBV inhibitors with a high genetic barrier to resistant mutants, so they are recommended by the current treatment guidelines as preferred first-line monotherapies. Failure of antiviral therapy for CHB results in a partial virological response and virological breakthrough, which are related to antiviral-resistant mutants. If genotypic resistance is confirmed, rescue therapy should be initiated, and the regimen should include a potent drug without cross-resistance to prior antiviral agents to minimize the risk of emergence of multiple drug-resistant mutants. This article reviews the current developments in oral antiviral agents, recommendations in CHB treatment guidelines, the medical insurance policy of Korea’s National Health Insurance, and the optimal strategies for using these drugs in clinical practice.

번역하기

참고문헌 (Reference)

1 Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study" 381 : 468-475, 2013

2 Yuen MF, "Prevention and manage-ment of drug resistance for antihepatitis B treatment" 9 : 256-264, 2009

3 Yim HJ, "Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade" 19 : 195-209, 2013

4 Fung J, "Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B" 66 : 2715-2725, 2011

5 Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B" 125 : 1714-1722, 2003

6 Ko SY, "Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to ente-cavir therapy" 47 : 1362-1367, 2012

7 Marcellin P, "Long-term efficacy and safety of adefovir dipivoxil for the treat-ment of hepatitis B e antigen-positive chronic hepatitis B" 48 : 750-758, 2008

8 Bum Su Choung, "Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Naïve Patients with Chronic Hepatitis B" 거트앤리버 발행위원회 6 (6): 486-492, 2012

9 Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of chronic hepatitis B" 18 : 109-162, 2012

10 Liaw YF, "Impact of therapy on the long-term outcome of chronic hepatitis B" 17 : 413-423, 2013